rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Silence Therapeutics Plc - American Depository Share

SLN · Nasdaq

Health CareBiotechnologyJust dropped out

SLN stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 7.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
67 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0
WhoDidSharesTraded
Richard Ian Griffiths10% ownersold2,792,82610 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold100,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold50,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold3,50010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold800,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold382,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold470,82010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold605,17410 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold120,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold60,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold100,00010 Aug 2026filed 13 Aug 2026
Richard Ian Griffiths10% ownersold865,1126 Jul 2026filed 7 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders67+16 on the quarter
New · exited20 · 4
Reported value$237.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Siren, L.L.C.added · filed 13 Aug 20263,311,438$36.4M+400,000+13.7%
TCG Crossover Management, LLCunchanged · filed 14 Aug 20263,033,560$33.3M00.0%
Redmile Group, LLCunchanged · filed 14 Aug 20262,164,777$23.8M00.0%
Nantahala Capital Management, LLCreduced · filed 14 Aug 20261,346,731$14.8M-800,000−37.3%
CITADEL ADVISORS LLCadded · filed 14 Aug 20261,329,625$14.6M+94,818+7.7%
Nextech Invest Ltd.unchanged · filed 14 Aug 2026952,400$10.5M00.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026909,279$10.0M-164,912−15.4%
Ikarian Capital, LLCreduced · filed 14 Aug 2026830,784$1.8M-35,000−4.0%
Tetragon Partners GP Ltdadded · filed 13 Aug 2026764,256$8.4M+134,095+21.3%
Soleus Capital Management, L.P.new · filed 11 Aug 2026630,000$6.9M+630,000
31 Mar 2023 – 30 Jun 2026
274766Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Richard Ian Griffiths Company insider10% owner · last 10 Aug 20260 · 0
David Lemus Company insiderDirector · last 2 Jan 20260 · 0
James Ede-Golightly Company insiderDirector · last 2 Jan 20260 · 0
Rhonda Lynette Hellums Company insiderChief Financial Officer · last 2 Jan 20260 · 0
Steven J. Romano Company insiderEVP and Chief R&D Officer · last 2 Jan 20260 · 0
Timothy McInerney Company insiderDirector · last 2 Jan 20260 · 0
Iain Ross Company insiderInterim PEO · last 18 Dec 20250 · 0
Craig A. Tooman Company insiderPresident and CEO · last 2 Jan 20250 · 0
Michael H. Davidson Company insiderDirector · last 2 Jan 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202561.5%
Operating profit marginFY 2024 · to 31 Dec 2024-146%
Free cash flow marginFY 2024 · to 31 Dec 2024-157%
Return on capital employedFY 2025 · to 31 Dec 2025-77.3%
Research spendFY 2024 · to 31 Dec 2024157%
Share count trendFY 2025 · to 31 Jan 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$11.3M
Free cash flowFY 2025 · to 31 Dec 2025−$62.3M

Analyst forecasts

No analyst forecasts yet.